Session R.A. II 4
4 · Taysha Gene Therapies, Inc. · Filed Jun 22, 2023
Insider Transaction Report
Form 4
Session R.A. II
DirectorPresident and CEO10% Owner
Transactions
- Sale
Common Stock
2023-06-20$0.71/sh−295,653$210,209→ 9,125,189 total - Sale
Common Stock
2023-06-21$0.70/sh−138,962$97,635→ 8,986,227 total
Holdings
- 141,090(indirect: See footnote)
Common Stock
- 141,090(indirect: See footnote)
Common Stock
Footnotes (4)
- [F1]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.70 - $0.78. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F2]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.70 - $0.719. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The securities are held by RA Session II, as Trustee of the Session 2020 Annuity Trust I.
- [F4]The securities are held by RA Session II, as Trustee of the Session 2020 Annuity Trust II.